Incidence of Second Malignancies Among Patients Treated With Proton Versus Photon Radiation

被引:190
|
作者
Chung, Christine S. [1 ]
Yock, Torunn I. [2 ]
Nelson, Kerrie [3 ]
Xu, Yang [4 ]
Keating, Nancy L. [4 ,6 ]
Tarbell, Nancy J. [2 ,5 ]
机构
[1] Alta Bates Summit Med Ctr, Dept Radiat Oncol, Berkeley, CA USA
[2] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA
[3] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
[4] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Off Execut Dean, Boston, MA USA
[6] Brigham & Womens Hosp, Dept Gen Internal Med, Boston, MA 02115 USA
关键词
THERAPY; CANCERS; RISK; RADIOTHERAPY; NEUTRONS; LYMPHOMA; TUMORS;
D O I
10.1016/j.ijrobp.2013.04.030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Proton radiation, when compared with photon radiation, allows delivery of increased radiation dose to the tumor while decreasing dose to adjacent critical structures. Given the recent expansion of proton facilities in the United States, the long-term sequelae of proton therapy should be carefully assessed. The objective of this study was to compare the incidence of second cancers in patients treated with proton radiation with a population-based cohort of matched patients treated with photon radiation. Methods and Materials: We performed a retrospective cohort study of 558 patients treated with proton radiation from 1973 to 2001 at the Harvard Cyclotron in Cambridge, MA and 558 matched patients treated with photon therapy in the Surveillance, Epidemiology, and End Results (SEER) Program cancer registry. Patients were matched by age at radiation treatment, sex, year of treatment, cancer histology, and site. The main outcome measure was the incidence of second malignancies after radiation. Results: We matched 558 proton patients with 558 photon patients from the Surveillance, Epidemiology, and End Results registry. The median duration of follow-up was 6.7 years (interquartile range, 7.4) and 6.0 years (interquartile range, 9.3) in the proton and photon cohorts, respectively. The median age at treatment was 59 years in each cohort. Second malignancies occurred in 29 proton patients (5.2%) and 42 photon patients (7.5%). After we adjusted for sex, age at treatment, primary site, and year of diagnosis, proton therapy was not associated with an increased risk of second malignancy (adjusted hazard ratio, 0.52 [95% confidence interval, 0.32-0.85]; P = .009). Conclusions: The use of proton radiation therapy was not associated with a significantly increased risk of secondary malignancies compared with photon therapy. Longer follow-up of these patients is needed to determine if there is a significant decrease in second malignancies. Given the limitations of the study, these results should be viewed as hypothesis generating. (C) 2013 Elsevier Inc.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 50 条
  • [41] Predicted Cardiac and Second Cancer Risks in Hodgkin Lymphoma Patients Treated With Advanced Proton Beam Therapy Compared to Photon Radiation Therapy
    Ntentas, G.
    Dedeckova, K.
    Andrilik, M.
    Aznar, M. C.
    George, B.
    Darby, S. C.
    Cutter, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : S181 - S181
  • [42] Incidence of Second Primary Malignancies in Patients with Neuroendocrine Tumours
    Clift, Ashley K.
    Drymousis, Panagiotis
    Al-Nahhas, Adil
    Wasan, Harpreet
    Martin, John
    Holm, Sture
    Frilling, Andrea
    NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 26 - 32
  • [43] Incidence of Second Primary Malignancies In Patients With Primary Myelofibrosis
    Allepuz, Alejandro
    Sarnecka, Aleksandra
    Sablinska, Katarzyna
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 84 - 85
  • [44] IQ change within three years of radiation therapy in pediatric brain tumor patients treated with proton beam radiation therapy versus photon radiation therapy.
    Kahalley, Lisa
    Okcu, A. Fatih
    Ris, M. Douglas
    Grosshans, David
    Paulino, Arnold
    Chintagumpala, Murali M.
    Moore, Bartlett
    Stancel, Heather
    Wickham, Robert
    Mehta, Paras
    Mahajan, Anita
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Second primary malignancies among cancer patients
    Zheng, Xuanqi
    Li, Xiao
    Wang, Minqi
    Shen, Jianfei
    Sisti, Giovanni
    He, Zelai
    Huang, Jinfeng
    Li, Yan Michael
    Wu, Aimin
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (10)
  • [46] Risk of major cardiac events following adjuvant proton versus photon radiation therapy for patients with thymic malignancies (vol 56, pg 1060, 2017)
    Vogel, J.
    Lin, L.
    Simone, C. B., II
    Berman, A. T.
    ACTA ONCOLOGICA, 2018, 57 (06) : 873 - 873
  • [47] Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia
    Gugliotta, Gabriele
    Castagnetti, Fausto
    Breccia, Massimo
    Albano, Francesco
    Iurlo, Alessandra
    Intermesoli, Tamara
    Abruzzese, Elisabetta
    Levato, Luciano
    D'Adda, Mariella
    Pregno, Patrizia
    Cavazzini, Francesco
    Stagno, Fabio
    Martino, Bruno
    La Barba, Gaetano
    Sora, Federica
    Tiribelli, Mario
    Bigazzi, Catia
    Binotto, Gianni
    Bonifacio, Massimiliano
    Caracciolo, Clementina
    Soverini, Simona
    Foa, Robin
    Cavo, Michele
    Martinelli, Giovanni
    Pane, Fabrizio
    Saglio, Giuseppe
    Baccarani, Michele
    Rosti, Gianantonio
    HAEMATOLOGICA, 2017, 102 (09) : 1530 - 1536
  • [48] Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide
    Rifkin, Robert M.
    Abonour, Rafat
    Shah, Jatin J.
    Mehta, Jayesh
    Narang, Mohit
    Terebelo, Howard
    Gasparetto, Cristina
    Toomey, Kathleen
    Hardin, James W.
    Lu, Jane Jie
    Kenvin, Laurie
    Srinivasan, Shankar
    Knight, Robert
    Nagarwala, Yasir
    Durie, Brian G. M.
    LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2228 - 2231
  • [49] LONGITUDINAL COMPARISON OF NEUROCOGNITIVE TRAJECTORIES IN PEDIATRIC MEDULLOBLASTOMA PATIENTS TREATED WITH PROTON VERSUS PHOTON RADIOTHERAPY
    Kahalley, Lisa
    Peterson, Rachel
    Ris, M. Douglas
    Janzen, Laura
    Okcu, M. Fatih
    Grosshans, David
    Ramaswamy, Vijay
    Paulino, Arnold
    Hodgson, David
    Mahajan, Anita
    Tsang, Derek
    Laperriere, Normand
    Whitehead, William
    Dauser, Robert
    Taylor, Michael
    Conklin, Heather
    Bouffet, Eric
    Chintagumpala, Murali
    Mabbott, Donald
    NEURO-ONCOLOGY, 2020, 22 : 431 - 431
  • [50] Neurocognitive Outcomes in Pediatric Neuro-Oncology Patients Treated with Photon versus Proton Radiotherapy
    Peterson, R. K.
    Katzenstein, J.
    CLINICAL NEUROPSYCHOLOGIST, 2017, 31 (04) : 741 - 741